Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew Bryant

Showing results (41-50 of 51) with videos related to

Pageof 6
Sort By:
Journal of Medicinal Chemistry|September 16, 2005
Discovery of potent orally active thrombin receptor (protease activated receptor 1) antagonists as novel antithrombotic agentsSamuel Chackalamannil, Yan Xia, William J Greenlee, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 22, 2003
Pharmacological characterization of the novel histamine H3-receptor antagonist N-(3,5-dichlorophenyl)-N'-[[4-(1H-imidazol-4-ylmethyl)phenyl]-methyl]-urea (SCH 79687)Robbie L McLeod, Charlie A Rizzo, Robert E West, et al.
Bioorganic & Medicinal Chemistry Letters|December 29, 2005
Discovery and synthesis of a novel series of quinoline-based thrombin receptor (PAR-1) antagonistsMartin C Clasby, Samuel Chackalamannil, Michael Czarniecki, et al.
International Journal of Environmental Research and Public Health|February 15, 2022
Clinician Perspectives of Communication with Aboriginal and Torres Strait Islanders Managing Pain: Needs and PreferencesChristina M Bernardes, Stuart Ekberg, Stephen Birch, et al.
Journal of Medicinal Chemistry|September 15, 2007
Heterotricyclic himbacine analogs as potent, orally active thrombin receptor (protease activated receptor-1) antagonistsMariappan V Chelliah, Samuel Chackalamannil, Yan Xia, et al.
Bioorganic & Medicinal Chemistry Letters|April 18, 2002
Identification of a novel, orally bioavailable histamine H(3) receptor antagonist based on the 4-benzyl-(1H-imidazol-4-yl) templateRobert Aslanian, Mwangi W Mutahi, Neng Yang Shih, et al.
Journal of Medicinal Chemistry|January 5, 2007
Metabolism-based identification of a potent thrombin receptor antagonistMartin C Clasby, Samuel Chackalamannil, Michael Czarniecki, et al.
Frontiers in Pharmacology|May 1, 2024
The effect of black cohosh extract and risedronate coadministration on bone health in an ovariectomized rat modelAmy L Inselman, Elysia A Masters, Jalina N Moore, et al.
Reproductive Toxicology (Elmsford, N.Y.)|August 2, 2015
NIEHS/FDA CLARITY-BPA research program updateJerrold J Heindel, Retha R Newbold, John R Bucher, et al.
Bioorganic & Medicinal Chemistry Letters|November 22, 2005
Reduction of CYP450 inhibition in the 4-[(1H-imidazol-4-yl)methyl]piperidine series of histamine H3 receptor antagonistsMichael Berlin, Pauline C Ting, Wayne D Vaccaro, et al.
Pageof 6

Showing results (41-50 of 51) with videos related to

Sort By:
Pageof 6
Journal of Medicinal Chemistry|September 16, 2005
Discovery of potent orally active thrombin receptor (protease activated receptor 1) antagonists as novel antithrombotic agentsSamuel Chackalamannil, Yan Xia, William J Greenlee, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 22, 2003
Pharmacological characterization of the novel histamine H3-receptor antagonist N-(3,5-dichlorophenyl)-N'-[[4-(1H-imidazol-4-ylmethyl)phenyl]-methyl]-urea (SCH 79687)Robbie L McLeod, Charlie A Rizzo, Robert E West, et al.
Bioorganic & Medicinal Chemistry Letters|December 29, 2005
Discovery and synthesis of a novel series of quinoline-based thrombin receptor (PAR-1) antagonistsMartin C Clasby, Samuel Chackalamannil, Michael Czarniecki, et al.
International Journal of Environmental Research and Public Health|February 15, 2022
Clinician Perspectives of Communication with Aboriginal and Torres Strait Islanders Managing Pain: Needs and PreferencesChristina M Bernardes, Stuart Ekberg, Stephen Birch, et al.
Journal of Medicinal Chemistry|September 15, 2007
Heterotricyclic himbacine analogs as potent, orally active thrombin receptor (protease activated receptor-1) antagonistsMariappan V Chelliah, Samuel Chackalamannil, Yan Xia, et al.
Bioorganic & Medicinal Chemistry Letters|April 18, 2002
Identification of a novel, orally bioavailable histamine H(3) receptor antagonist based on the 4-benzyl-(1H-imidazol-4-yl) templateRobert Aslanian, Mwangi W Mutahi, Neng Yang Shih, et al.
Journal of Medicinal Chemistry|January 5, 2007
Metabolism-based identification of a potent thrombin receptor antagonistMartin C Clasby, Samuel Chackalamannil, Michael Czarniecki, et al.
Frontiers in Pharmacology|May 1, 2024
The effect of black cohosh extract and risedronate coadministration on bone health in an ovariectomized rat modelAmy L Inselman, Elysia A Masters, Jalina N Moore, et al.
Reproductive Toxicology (Elmsford, N.Y.)|August 2, 2015
NIEHS/FDA CLARITY-BPA research program updateJerrold J Heindel, Retha R Newbold, John R Bucher, et al.
Bioorganic & Medicinal Chemistry Letters|November 22, 2005
Reduction of CYP450 inhibition in the 4-[(1H-imidazol-4-yl)methyl]piperidine series of histamine H3 receptor antagonistsMichael Berlin, Pauline C Ting, Wayne D Vaccaro, et al.
Pageof 6